Analyses of VEGF levels, endocan levels, clinical characteristics, and laboratory findings between the patient groups classified based on neoadjuvant chemotherapy receiving status, smoking status, presence of type II diabetes mellitus, secondary pulmonary disease, and cardiovascular disease revealed no statistically significant differences, other than in endocan levels on postoperative day 30, which were significantly higher in the smoking group than in the non-smoking group (p = 0.043). Here, VEGFA is linked to lung disorder.